Pneumococcal Polysaccharide Vaccination (PPV23) Vaccination and Risk of Cardiovascular Events: A Meta-Analysis
Authors' conclusion
Current evidence remains insufficient to establish a cardiovascular benefit of PPV23. Further adequately powered evidence is needed to resolve the remaining uncertainty.
Study context
- Population
- Studies comparing PPV23 with placebo or no vaccination reporting acute coronary syndrome (ACS) events, stroke, or all-cause mortalitystudies: 2 randomized trials and 4 propensity-adjusted cohort studies · randomized trials 2 · propensity-adjusted cohort studies 4
- Participants
- 6 participants
- Comparison
- PPV23 with placebo or no vaccination
- Outcome
- ACS events (Bayesian analysis)
Methodological detailssystematic search of MEDLINE, Embase, and Cochrane CENTRAL, randomized controlled trials and propensity-adjusted observational cohort studies
- Systematic search of MEDLINE, Embase, and Cochrane CENTRAL
- Randomized controlled trials and propensity-adjusted observational cohort studies
Pooled result
As reported in the abstract
Posterior probability of any benefit
85%
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| Stroke (Bayesian analysis) | 1.10 (0.83–1.48) | |
| All-cause mortality (Bayesian analysis) | 1.02 (0.83–1.29) | |
| 0.512Hazard ratio (log scale) |
Frequentist analyses
- Directionally consistent, with 95% CIs crossing the null for ACS events, stroke, and all-cause mortality
Certainty of evidence (GRADE)
- Low across all outcomes
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
PPV23 Vaccination and Risk of Cardiovascular Events: A Meta-Analysis. JACC Adv. Published 17 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →